8-K: Intelligent Bio Solutions Inc. Reports Strong Revenue Growth in Preliminary Q2 Results

Intelligent Bio Solutions Inc. announced a 114% year-over-year revenue increase for the second fiscal quarter and a 337% increase for the six months ended December 31, 2023.

Summary

• Intelligent Bio Solutions Inc. (INBS) has released preliminary unaudited revenue results for the second fiscal quarter and six months ended December 31, 2023.
• The company reported approximately $0.76 million in revenue for the second quarter, a 114% increase compared to the same period last year.
• For the six months ended December 31, 2023, the company expects approximately $1.56 million in revenue, a 337% increase year-over-year.
• INBS also anticipates a 30% increase in cartridge sales and a 91% increase in reader sales for the six months ended December 31, 2023, compared to the same period in 2022.
• The company attributes this growth to increased awareness of their drug screening solution, entry into new markets, and expansion of their global footprint.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the exceptionally high revenue growth and strong sales figures. The company's expansion plans and optimistic outlook further contribute to the positive sentiment.

Positives

• The company experienced substantial revenue growth, with a 114% increase in Q2 and a 337% increase over six months.
• There is a significant increase in both cartridge and reader sales, indicating strong product adoption.
• The company is actively expanding its global footprint, including entry into new markets like New Zealand and planned expansion in Asia-Pacific.
• Management is optimistic about maintaining this upward trajectory throughout 2024.

Risks

• The preliminary revenue results are subject to adjustments based on the company's completion of its quarter-end financial close process.
• The company's future success depends on its ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from partnerships, and secure regulatory approvals.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company aims to maintain its upward revenue trajectory throughout 2024 and anticipates further market expansion in the Asia-Pacific region.

Management Comments

• Spiro Sakiris, Chief Financial Officer, stated that the Q2 and six-month results are very encouraging, showing strong growth compared to 2022.
• Harry Simeonidis, President and Chief Executive Officer, noted that product sales are steadily rising due to increased awareness, entry into new markets, and expansion of their global footprint.
• Harry Simeonidis also mentioned that the revenue growth numbers indicate an increasing need for an efficient drug screening solution.

Industry Context

The announcement highlights the growing demand for rapid, non-invasive drug screening solutions, which aligns with the broader trend of increased workplace safety and health monitoring. The company's technology, using fingerprint sweat analysis, positions it as a potential disruptor in the portable testing market.

Comparison to Industry Standards

• While specific competitor data is not provided, the 114% and 337% revenue growth figures are exceptionally high, suggesting that Intelligent Bio Solutions is outperforming many established players in the medical technology sector.
• Companies like Abbott and Roche, which are major players in diagnostics, typically see more moderate growth rates, making INBS's performance noteworthy.
• The focus on fingerprint-based drug screening is a unique approach compared to traditional blood or urine tests, potentially giving INBS a competitive edge in specific markets.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and expansion plans.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to an innovative drug screening solution.
• Suppliers may see increased demand for their products and services.

Next Steps

• The company expects to disclose full financial results in its upcoming Quarterly Report on Form 10-Q.
• The company plans to continue its market expansion throughout the Asia-Pacific region.

Key Dates

Keywords

drug screening, medical technology, revenue growth, fingerprint analysis, biosensor, non-invasive testing, cartridge sales, reader sales